Cargando…
Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
Over the past decade, theranostic imaging has emerged as a powerful clinical tool in oncology for identifying patients likely to respond to targeted therapies and for monitoring the response of patients to treatment. Herein, we report a theranostic approach to pretargeted radioimmunotherapy (PRIT) b...
Autores principales: | Keinänen, Outi, Fung, Kimberly, Brennan, James M., Zia, Nicholas, Harris, Matt, van Dam, Ellen, Biggin, Colin, Hedt, Amos, Stoner, Jon, Donnelly, Paul S., Lewis, Jason S., Zeglis, Brian M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668034/ https://www.ncbi.nlm.nih.gov/pubmed/33106429 http://dx.doi.org/10.1073/pnas.2009960117 |
Ejemplares similares
-
Pretargeted Molecular Imaging and Radioimmunotherapy
por: Goldenberg, David M., et al.
Publicado: (2012) -
Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013) -
Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023) -
Pretargeting of internalizing trastuzumab and cetuximab with a (18)F-tetrazine tracer in xenograft models
por: Keinänen, Outi, et al.
Publicado: (2017) -
Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)